Notable Price Action: What Next for Alcobra Ltd Stock After Today’s Huge Decline?

Notable Price Action: What Next for Alcobra Ltd Stock After Today's Huge Decline?

The stock of Alcobra Ltd (NASDAQ:ADHD) is a huge mover today! The stock decreased 1.59% or $0.04 during the last trading session, hitting $2.47. About 1.74M shares traded hands or 297.32% up from the average. Alcobra Ltd (NASDAQ:ADHD) has declined 47.00% since February 29, 2016 and is downtrending. It has underperformed by 57.42% the S&P500.
The move comes after 9 months negative chart setup for the $36.98M company. It was reported on Oct, 1 by Barchart.com. We have $2.22 PT which if reached, will make NASDAQ:ADHD worth $3.70M less.

Alcobra Ltd (NASDAQ:ADHD) Ratings Coverage

Out of 6 analysts covering Alcobra (NASDAQ:ADHD), 3 rate it a “Buy”, 0 “Sell”, while 3 “Hold”. This means 50% are positive. Alcobra has been the topic of 11 analyst reports since August 9, 2015 according to StockzIntelligence Inc. Barclays Capital initiated Alcobra Ltd (NASDAQ:ADHD) on Monday, August 1 with “Equal-Weight” rating. The firm earned “Buy” rating on Tuesday, June 21 by Roth Capital. Zacks upgraded Alcobra Ltd (NASDAQ:ADHD) on Monday, August 17 to “Hold” rating. As per Thursday, February 18, the company rating was initiated by Jefferies. The firm has “Buy” rating by Roth Capital given on Thursday, February 4. The rating was downgraded by Cantor Fitzgerald on Thursday, September 29 to “Hold”. The stock of Alcobra Ltd (NASDAQ:ADHD) earned “Outperform” rating by Oppenheimer on Monday, January 25. As per Tuesday, June 7, the company rating was initiated by Cantor Fitzgerald. The company was downgraded on Thursday, September 29 by Oppenheimer. The stock of Alcobra Ltd (NASDAQ:ADHD) has “Hold” rating given on Sunday, August 9 by WBB Securities.

According to Zacks Investment Research, “Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel.”

More news for Alcobra Ltd (NASDAQ:ADHD) were recently published by: Globenewswire.com, which released: “Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study” on September 29, 2016. Quotes.Wsj.com‘s article titled: “Alcobra Ltd. ADHD (US: Nasdaq)” and published on May 18, 2013 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment